The EPS miss and decision to skip the Q2 earnings call signal operational challenges and acquisition-related uncertainty. Traders should watch for closing details of the Theravance Biopharma deal and any updated guidance on the combined entity's financial outlook.
Price Chart
Executive Summary
Zymeworks reported Q1 2026 EPS of -$0.59, a 31.6% miss versus consensus of -$0.45, with revenue of $18.1M in line with estimates. The company announced it will not host a Q2 2026 earnings call due to the pending Theravance Biopharma acquisition, creating uncertainty around near-term financial visibility.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.59 missed consensus of -$0.45 by 31.6%
- Revenue of $18.1M in line with consensus
- No Q2 2026 earnings conference call due to pending Theravance Biopharma acquisition
- EPS miss extends a trend of negative surprises (Q4 2025: -$0.55 vs -$0.35 consensus)
Financial Impact
EPS miss of 31.6% on a -$0.14 per share gap vs consensus
Risk Factors
- Acquisition integration risk and delayed financial visibility
- Continued EPS deterioration trend over recent quarters
- Potential dilution or restructuring from the Theravance Biopharma deal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3328292 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 8-K | $27.47 $27.50 | ▲ +0.11% | ▼ −0.87% | $25.18 (−8.32%) |
Jul 16, 2026 11w ago | Press Release | $24.19 $25.76 | ▼ −6.49% | ▼ −2.87% | $25.18 (−4.11%) |
Jun 29, 2026 13w ago | Press Release | $24.10 $22.86 | ▼ −5.15% | ▼ −4.87% | $25.18 (+4.50%) |
Jun 14, 2026 15w ago | Press Release | $23.26 $24.94 | ▲ +7.22% | ▲ +7.97% | $25.18 (+8.28%) |
May 15, 2026 19w ago | 3 | $24.43 $22.49 | ▼ −7.94% | ▼ −9.52% | $25.18 (+3.09%) |
Apr 21, 2026 23w ago | Press Release | $28.53 $24.40 | ▼ −14.48% | ▼ −17.64% | $25.18 (−11.72%) |
Apr 17, 2026 23w ago | Press Release | $27.80 $23.96 | ▼ −13.81% | ▼ −19.18% | $25.18 (−9.41%) |
Apr 16, 2026 24w ago | Press Release | $27.20 $24.57 | ▼ −9.67% | ▼ −15.48% | $25.18 (−7.41%) |
Apr 10, 2026 24w ago | 3 | $26.17 $24.03 | ▼ −8.18% | ▼ −15.91% | $25.18 (−3.76%) |
Mar 17, 2026 28w ago | Press Release | $23.45 $27.20 | ▲ +15.99% | ▲ +9.94% | $25.18 (+7.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access